Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.79
SKBI's Cash to Debt is ranked higher than
64% of the 910 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. SKBI: 0.79 )
SKBI' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: 0.79

Equity to Asset 0.71
SKBI's Equity to Asset is ranked higher than
78% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. SKBI: 0.71 )
SKBI' s 10-Year Equity to Asset Range
Min: -8.64   Max: 0.91
Current: 0.71

-8.64
0.91
Interest Coverage 21.26
SKBI's Interest Coverage is ranked higher than
62% of the 550 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 104.14 vs. SKBI: 21.26 )
SKBI' s 10-Year Interest Coverage Range
Min: 0.99   Max: 9999.99
Current: 21.26

0.99
9999.99
F-Score: 6
Z-Score: 2.05
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 25.69
SKBI's Operating margin (%) is ranked higher than
94% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.67 vs. SKBI: 25.69 )
SKBI' s 10-Year Operating margin (%) Range
Min: -50916.67   Max: 38.08
Current: 25.69

-50916.67
38.08
Net-margin (%) 22.48
SKBI's Net-margin (%) is ranked higher than
94% of the 861 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.48 vs. SKBI: 22.48 )
SKBI' s 10-Year Net-margin (%) Range
Min: -75166.67   Max: 29.63
Current: 22.48

-75166.67
29.63
ROE (%) 9.78
SKBI's ROE (%) is ranked higher than
81% of the 882 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. SKBI: 9.78 )
SKBI' s 10-Year ROE (%) Range
Min: -56375   Max: 50.25
Current: 9.78

-56375
50.25
ROA (%) 7.49
SKBI's ROA (%) is ranked higher than
85% of the 914 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. SKBI: 7.49 )
SKBI' s 10-Year ROA (%) Range
Min: -60200   Max: 28.07
Current: 7.49

-60200
28.07
ROC (Joel Greenblatt) (%) 11.90
SKBI's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 908 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.66 vs. SKBI: 11.90 )
SKBI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6431.58   Max: 50.28
Current: 11.9

-6431.58
50.28
Revenue Growth (3Y)(%) -5.90
SKBI's Revenue Growth (3Y)(%) is ranked higher than
57% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.60 vs. SKBI: -5.90 )
SKBI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 37.1
Current: -5.9

0
37.1
EBITDA Growth (3Y)(%) -8.80
SKBI's EBITDA Growth (3Y)(%) is ranked higher than
61% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. SKBI: -8.80 )
SKBI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 28.8
Current: -8.8

0
28.8
EPS Growth (3Y)(%) -11.20
SKBI's EPS Growth (3Y)(%) is ranked higher than
65% of the 675 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. SKBI: -11.20 )
SKBI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 53.3
Current: -11.2

0
53.3
» SKBI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SKBI Guru Trades in

SKBI Guru Trades in

SKBI Guru Trades in

Q3 2014

SKBI Guru Trades in Q3 2014

Jim Simons 14,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SKBI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3.30
SKBI's P/E(ttm) is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.00 vs. SKBI: 3.30 )
SKBI' s 10-Year P/E(ttm) Range
Min: 0.78   Max: 486.49
Current: 3.3

0.78
486.49
P/B 0.31
SKBI's P/B is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. SKBI: 0.31 )
SKBI' s 10-Year P/B Range
Min: 0.09   Max: 6.88
Current: 0.31

0.09
6.88
P/S 0.73
SKBI's P/S is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.89 vs. SKBI: 0.73 )
SKBI' s 10-Year P/S Range
Min: 0.22   Max: 35.13
Current: 0.73

0.22
35.13
PFCF 1.98
SKBI's PFCF is ranked higher than
100% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SKBI: 1.98 )
SKBI' s 10-Year PFCF Range
Min: 1.45   Max: 80.18
Current: 1.98

1.45
80.18
EV-to-EBIT 3.39
SKBI's EV-to-EBIT is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.22 vs. SKBI: 3.39 )
SKBI' s 10-Year EV-to-EBIT Range
Min: 0.6   Max: 39.8
Current: 3.39

0.6
39.8
Shiller P/E 2.84
SKBI's Shiller P/E is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 165.76 vs. SKBI: 2.84 )
SKBI' s 10-Year Shiller P/E Range
Min: 0.94   Max: 1090
Current: 2.84

0.94
1090
Current Ratio 2.50
SKBI's Current Ratio is ranked higher than
72% of the 893 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. SKBI: 2.50 )
SKBI' s 10-Year Current Ratio Range
Min: 0.01   Max: 9.57
Current: 2.5

0.01
9.57
Quick Ratio 2.02
SKBI's Quick Ratio is ranked higher than
74% of the 892 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. SKBI: 2.02 )
SKBI' s 10-Year Quick Ratio Range
Min: 0.01   Max: 7.56
Current: 2.02

0.01
7.56

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.27
SKBI's Price/Net Current Asset Value is ranked higher than
89% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. SKBI: 9.27 )
SKBI' s 10-Year Price/Net Current Asset Value Range
Min: 1.13   Max: 173.33
Current: 9.27

1.13
173.33
Price/Tangible Book 0.32
SKBI's Price/Tangible Book is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.24 vs. SKBI: 0.32 )
SKBI' s 10-Year Price/Tangible Book Range
Min: 0.1   Max: 7.07
Current: 0.32

0.1
7.07
Price/DCF (Projected) 0.30
SKBI's Price/DCF (Projected) is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.02 vs. SKBI: 0.30 )
SKBI' s 10-Year Price/DCF (Projected) Range
Min: 0.12   Max: 152.5
Current: 0.3

0.12
152.5
Price/Median PS Value 0.60
SKBI's Price/Median PS Value is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. SKBI: 0.60 )
SKBI' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 49.23
Current: 0.6

0.22
49.23
Price/Graham Number 0.22
SKBI's Price/Graham Number is ranked higher than
100% of the 949 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.05 vs. SKBI: 0.22 )
SKBI' s 10-Year Price/Graham Number Range
Min: 0.08   Max: 5.07
Current: 0.22

0.08
5.07
Earnings Yield (Greenblatt) 29.50
SKBI's Earnings Yield (Greenblatt) is ranked higher than
99% of the 907 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. SKBI: 29.50 )
SKBI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.5   Max: 157
Current: 29.5

2.5
157
Forward Rate of Return (Yacktman) 4.40
SKBI's Forward Rate of Return (Yacktman) is ranked higher than
73% of the 497 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. SKBI: 4.40 )
SKBI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -49.5   Max: 5.6
Current: 4.4

-49.5
5.6

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:GNJC.Germany,
Skystar Bio-Pharmaceutical Company was incorporated in Nevada on September 24, 1998. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People's Republic of China. The Company's operations are carried out by Xi'an Tianxing Bio-Pharmaceutical Co., Limited, a PRC joint stock company that it controls through contractual arrangements originally between Skystar Cayman and Xi'an Tianxing. The Company has four major product lines, namely micro-organism products line; veterinary medicine line; feed additives line; bio-pharmaceutical veterinary vaccine line. Its micro-organism products line includes over 16 products; veterinary medicine line for poultry and livestock includes over 245 products; feed additives line includes over 16 products; and its bio-pharmaceutical veterinary vaccine line includes over 10 products. As of December 31, 2012, the Company had over 4,000 customers in 29 provinces in China, including 2,893 distributors and 1,122 direct customers. Of the 2,893 distributors, 360 are physical stores that have outer signage with its logo and sell products from its four product lines, known as franchise distributors. The Company competes with China Animal Husbandry Industry Co. Ltd. and Qilu Animal Health Production Co., Ltd. in China. In veterinary vaccine products, the Company competes with Xinjiang Tecon Animal Husbandry Bio-technology Co., Ltd. and Inner Mongolia Jinyu Group Stock Company.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK